Overview

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.
Phase:
Phase 3
Details
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Treatments:
Apomorphine